Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | QPCT | Q16769 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.34 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177857 | 1.00 | PIK3CA (0.49) | PIK3CAPIK3CDPIK3CBSYKQPCT | |
| SCHEMBL16742224 | 0.80 | PIK3CD (0.57) | PIK3CAPIK3CDPIK3CBSYKQPCT | |
| SCHEMBL21187296 | 0.79 | SYK (0.47) | SYKTBK1 | |
| SCHEMBL21178138 | 0.79 | SYK (0.47) | SYKTBK1 | |
| SCHEMBL30817825 | 0.79 | SYK (0.47) | SYKTBK1 | |
| SCHEMBL4033516 | 0.79 | SYK (0.39) | PIK3CAPIK3CDPIK3CBSYKIP6K1 | |
| SCHEMBL16747780 | 0.78 | PIK3CD (0.39) | PIK3CAPIK3CDPIK3CBSYK | |
| SCHEMBL18128950 | 0.78 | PIK3CD (0.39) | PIK3CAPIK3CDPIK3CBSYK | |
| SCHEMBL18128959 | 0.78 | SYK (0.42) | PIK3CAPIK3CDPIK3CBSYKQPCT | |
| SCHEMBL21187399 | 0.78 | SYK (0.47) | SYKTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PIK3CA 271/4885PIK3CD 623/4885PIK3CB 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.